Seasonal allergic rhinitis

This early-stage trial tests an experimental RNA immunotherapy called ITI-9001 in adults with Japanese cedar pollen allergy. The treatment aims to retrain the immune system to reduce allergic reactions. Researchers are primarily checking safety and how well people tolerate the sh…

This study tests an experimental antihistamine called rupatifen fumarate for people with seasonal allergic rhinitis (hay fever). About 550 adults aged 18 to 65 with at least a 2-year history of seasonal allergies will take either the new drug, an existing antihistamine, or a plac…

This study tests whether an injection called stapokibart can reduce nasal allergy symptoms like runny nose, congestion, sneezing, and itching in adolescents aged 12 to 17 with seasonal allergic rhinitis (hay fever). Participants receive either stapokibart or a placebo alongside t…

This Phase 3 trial tests an investigational injection called SHR-1819 in adults aged 18 to 75 with seasonal allergic rhinitis (hay fever) who haven't gotten enough relief from standard treatments like nasal sprays or antihistamines. The study compares the drug to a placebo to see…

This study tests an injection called TQH2722 in 300 adults with seasonal allergic rhinitis (hay fever). The goal is to see if it safely eases symptoms like sneezing, stuffy nose, and itchy eyes when added to standard allergy treatments. Participants will receive the injection and…

This study tracks how adults with grass pollen allergy use Grassmuno® in everyday medical practice. Researchers will monitor treatment adherence and injection schedules over two years. The goal is to understand how well patients stick with the therapy and how it controls their sy…

This study tests a new nasal spray called ALDP001 for people with seasonal allergic rhinitis (hay fever). Researchers want to find the best dose and how often to use it to reduce symptoms like sneezing, stuffy nose, and runny nose. About 164 adults will take part, and their sympt…

This study tests a new antibody drug for people whose seasonal allergies (hay fever) are not controlled by standard treatments. The drug targets a protein involved in allergic inflammation. About 120 adults will receive either the antibody or a placebo, and researchers will measu…

This Phase 3 trial tests an injection called GR1802 for people with seasonal allergic rhinitis (hay fever) that is not well controlled by standard treatments. The drug is a lab-made antibody that blocks a key inflammation signal. About 150 adults will receive either GR1802 or a p…

This study aims to develop a blood test that measures B regulatory cells, which may indicate whether allergen immunotherapy (allergy shots) is successfully reducing allergic reactions. Researchers will study 80 adults with pollen or venom allergies who are starting routine allerg…

This study is looking for 530 adults with hay fever in South-Eastern Australia to help create a tool that predicts thunderstorm asthma. Participants will have allergy and lung function tests, then track their symptoms during spring for two years. The goal is to find warning signs…

This study is testing whether a nasal allergen provocation test (NAPT) can help doctors start and monitor allergy immunotherapy more effectively. Researchers will follow 200 adults with allergic rhinitis who are beginning immunotherapy, using the NAPT along with blood tests and s…